Consider Adverse Reactions to Anti-Sars-Cov-2 Compounds as Causes of Pediatric Neuro-Covid

Abstract

With interest we read the article byLaRovere et al. about a retrospective analysis of 365 patients aged <21y  with  neurological  complications  ofclinically  manifesting  infection  with  SARS-CoV-2  (neuro-COVID).[1]  It  was  concluded  that  neuro-COVID  in  this  cohort  was  frequently  mild  and  transient  and that   only   43   patients   (11,7%)   experienced   life-threatening   neurological   complications,   such   as encephalopathy  (n=15),  Ischämie/hemorrhaghic  stroke  (n=12),  CNS-infection/ADEM  (n=8),  cerebral edema (n=4), or Guillain-Barre syndrome (n=4).[1] We have the following comments and concerns